<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508027</url>
  </required_header>
  <id_info>
    <org_study_id>1R01FD003080-01A1</org_study_id>
    <nct_id>NCT00508027</nct_id>
  </id_info>
  <brief_title>Simvastatin (Zocor) Therapy in Sickle Cell Disease</brief_title>
  <official_title>Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent clinical and experimental data indicate that statins have effects beyond cholesterol
      lowering that may be beneficial in sickle cell disease by protecting the vascular
      endothelium. Statins have been shown to attenuate endothelial dysfunction through their
      anti-inflammatory, anti-oxidant and anti-thrombotic properties. This phase I/II
      dose-escalating trial is designed to assess the safety and potential clinical efficacy of
      oral simvastatin (Zocor)in adolescents and adults with sickle cell disease (SCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although statins have been used extensively for their cholesterol-lowering effects, recent
      clinical and experimental data indicate that statins regulate yet other processes, many of
      which play a major role in sickle cell disease (SCD). Independent of their
      cholesterol-lowering effects, statins have been shown to prevent damage to blood vessels in
      several ways, through upregulation of endothelial nitric oxide (NO)and decreased
      inflammation. Numerous studies documenting the protective effects of statins, together with
      data showing the therapeutic role of NO in SCD, provide the basis for investigating the
      potential clinical benefit of simvastatin in SCD.

      Data supporting the safety and tolerability of simvastatin in patients with SCD are now
      needed. For this phase I/II dose-escalation study of oral simvastatin in SCD, we propose the
      following specific aims:

        1. To obtain preliminary efficacy data on the effects of oral simvastatin on plasma
           biomarkers of endothelial injury in patients with SCD, and

        2. To assess the safety and tolerability of oral simvastatin in patients with SCD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Cholesterol Level</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in serum total cholesterol level after treatment with simvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hemoglobin Level</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in plasma hemoglobin (Hb) level after treatment with simvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Creatine Kinase Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in serum creatine kinase (CK) levels after treatment with simvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Alanine Transaminase (ALT) Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in serum alanine transaminase (ALT) after treatment with simvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Creatinine Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in serum creatinine (Cr) levels after treatment with simvastatin</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Plasma NOx Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasma Hs-CRP Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasma IL-6 Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in plasma IL-6 level after treatment with simvastatin</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasma VEGF Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasma VCAM1 Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Plasma TF Levels</measure>
    <time_frame>Baseline, 21 days</time_frame>
    <description>Change in plasma tissue factor (TF) levels after treatment with simvastatin</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Simvastatin, Dose Escalation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.</description>
    <arm_group_label>Simvastatin, Dose Escalation</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of sickle cell disease (HbSS, SC or Sβ-thalassemia)

          -  Age greater than or equal to thirteen years

          -  Weight greater than or equal to 35 kg

        Exclusion Criteria:

          -  Renal dysfunction (Serum Creatinine &gt; 1.5 UNL)

          -  Hepatic dysfunction (ALT &gt; 2X UNL)

          -  Pretreatment total cholesterol &lt; 100 mg/dL or triglycerides &lt; 30 mg/dL

          -  Pretreatment baseline creatine kinase &gt;1X UNL (215 U/L)

          -  Pregnancy/lactation

          -  RBC transfusion in the last 30 days

          -  Vaso-Occlusive Event needing hospitalization in the past 30 days

          -  Treatment with any statin drugs within the past 30 days

          -  Treatment with drugs having known metabolic interactions with statin drugs (e.g.
             cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole,
             erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin,
             coumadin, sildenafil or amiodarone within the past 30 days

          -  Treatment (past or present) with amiodarone

          -  Musculoskeletal disorder associated with an elevated creatine kinase level

          -  Past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin,
             PCP)

          -  Allergy to statins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn C Hoppe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital &amp; Research Center Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital and Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.childrenshospitaloakland.org</url>
    <description>Children's Hospital and Research Center Oakland Official Website</description>
  </link>
  <link>
    <url>http://www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhatIs.html</url>
    <description>NHLBI Website - Sickle Cell Disease</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/ency/article/000527.htm</url>
    <description>Medline Plus: Sickle Cell Anemia</description>
  </link>
  <link>
    <url>http://www.childrenshospitaloakland.org/healthcare/depts/sickle_cell_center.asp</url>
    <description>CHO Sickle Cell Program: National Center for Sickle Cell Disease</description>
  </link>
  <reference>
    <citation>Hebbel RP. Extracorpuscular factors in the pathogenesis of sickle cell disease. Am J Pediatr Hematol Oncol. 1982 Fall;4(3):316-9.</citation>
    <PMID>7149170</PMID>
  </reference>
  <reference>
    <citation>Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997 Jun 1;99(11):2561-4. Review.</citation>
    <PMID>9169483</PMID>
  </reference>
  <reference>
    <citation>Hebbel RP. Special issue of Microcirculation: examination of the vascular pathobiology of sickle cell anemia. Foreword. Microcirculation. 2004 Mar;11(2):99-100.</citation>
    <PMID>15280085</PMID>
  </reference>
  <reference>
    <citation>Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H293-301. Epub 2004 Mar 4.</citation>
    <PMID>15001449</PMID>
  </reference>
  <reference>
    <citation>Wood KC, Hebbel RP, Granger DN. Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice. Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1608-14. Epub 2004 Jan 2.</citation>
    <PMID>14704223</PMID>
  </reference>
  <reference>
    <citation>Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000 Oct 1;96(7):2451-9.</citation>
    <PMID>11001897</PMID>
  </reference>
  <reference>
    <citation>Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999 Dec 13-27;159(22):2661-7.</citation>
    <PMID>10597756</PMID>
  </reference>
  <reference>
    <citation>Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol. 2001 Dec 1;88(11):1306-7.</citation>
    <PMID>11728362</PMID>
  </reference>
  <reference>
    <citation>Hebbel RP, Vercellotti GM. The endothelial biology of sickle cell disease. J Lab Clin Med. 1997 Mar;129(3):288-93. Review.</citation>
    <PMID>9042813</PMID>
  </reference>
  <reference>
    <citation>Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997 Nov 27;337(22):1584-90.</citation>
    <PMID>9371854</PMID>
  </reference>
  <reference>
    <citation>Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998 May 1;101(9):1899-904.</citation>
    <PMID>9576754</PMID>
  </reference>
  <reference>
    <citation>Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol. 2003 Mar;10(2):99-107. Review.</citation>
    <PMID>12579034</PMID>
  </reference>
  <reference>
    <citation>Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med. 2004 Mar 15;36(6):707-17. Review.</citation>
    <PMID>14990351</PMID>
  </reference>
  <reference>
    <citation>Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000 Aug;106(3):337-8.</citation>
    <PMID>10930436</PMID>
  </reference>
  <reference>
    <citation>Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med. 2001 Jan-Feb;20(1):47-72.</citation>
    <PMID>12673844</PMID>
  </reference>
  <reference>
    <citation>Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9. Review.</citation>
    <PMID>11701455</PMID>
  </reference>
  <reference>
    <citation>Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999 Dec;84(3):413-28. Review. Erratum in: Pharmacol Ther 2000 May;86(2):199.</citation>
    <PMID>10665838</PMID>
  </reference>
  <results_reference>
    <citation>Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011 Jun;153(5):655-63. doi: 10.1111/j.1365-2141.2010.08480.x. Epub 2011 Apr 8.</citation>
    <PMID>21477202</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2007</study_first_posted>
  <results_first_submitted>February 11, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2013</results_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital &amp; Research Center Oakland</investigator_affiliation>
    <investigator_full_name>Carolyn Hoppe</investigator_full_name>
    <investigator_title>Associate Hematologist</investigator_title>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>simvastatin</keyword>
  <keyword>statin drugs</keyword>
  <keyword>nitric oxide donors</keyword>
  <keyword>vascular injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>During the study period (05/2006-09/2010), eligible adult and adolescent SCD subjects followed at the CHRCO Sickle Cell Center were approached about participation in this trial. Subjects were enrolled at “steady-state” (i.e., no acute illness or acute SCD-related complications) during a routine clinic visit.</recruitment_details>
      <pre_assignment_details>There were no significant events following enrollment after inclusion and exclusion criteria were met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin, 3 Escalating Dose Groups</title>
          <description>Simvastatin was given in a dose-escalating fashion to 3 sequential dose groups:
dose level 1= 20 mg/day, dose level 2= 40 mg/day, dose level 3= 80 mg/day The number of subjects starting each dose level are new cohorts of subjects.
Determination of clinical safety in the first dose level group was required in order to begin enrollment in the second dose level group and ultimately the third dose group. Enrollment in the third dose level was discontinued early due to newly reported FDA warnings regarding high dose (80mg/day) simvastatin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose Level 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">The participants starting each dose period is a new cohort of subjects. 20 subjects started dose 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dose Level 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">The participants starting each dose period is a new cohort of subjects. 20 new subjects in dose 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dose Level 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">enrollment discontinued due to FDA recommendations regarding high dose (80mg/day) simvastatin</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>42 subjects started the study; of these,12 were withdrawn from the study and 30 completed the study: dose level 1 (n=16); dose level 2 (n=12), dose level 3 (n=2). Only those participants who completed the study were included in the final analyses (n=30).</population>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin, Dose Escalation</title>
          <description>There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
Simvastatin : Comparison of 3 dosages of simvastatin given in a dose-escalating fashion.
20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sickle cell genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Homozygous Hb S (SS or S/beta0 thalassemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compound heterozygous Hb S and Hb C (SC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma NOx Levels</title>
        <description>Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group.</description>
        <time_frame>Baseline, 21 days</time_frame>
        <population>All participants for whom plasma biomarker levels were recorded at baseline and 21 days</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20mg simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; biomarker data were not collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma NOx Levels</title>
          <description>Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group.</description>
          <population>All participants for whom plasma biomarker levels were recorded at baseline and 21 days</population>
          <units>micromolar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="1"/>
                    <measurement group_id="O2" value="19.7" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ho: There is no change in plasma biomarker levels before and after simivastatin treatment. With 12 patients in each group and assuming a 5% risk of Type I error (two-tailed α = 0.05) and estimated SD for the change in NOx (or sVCAM-1) of 48%, power will be 80% to detect a 40% change from baseline for each group, and a 55% difference in the change in biomarker levels between dose groups. Matched paired t-tests were used to measure changes in biomarker levels from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma Hs-CRP Levels</title>
        <description>Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20mg simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Hs-CRP Levels</title>
          <description>Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="14.2"/>
                    <measurement group_id="O2" value="-3.6" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma IL-6 Levels</title>
        <description>Change in plasma IL-6 level after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20mg simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma IL-6 Levels</title>
          <description>Change in plasma IL-6 level after treatment with simvastatin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.9"/>
                    <measurement group_id="O2" value="-0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma VEGF Levels</title>
        <description>Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>All participants received 20mg simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma VEGF Levels</title>
          <description>Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-164" spread="40"/>
                    <measurement group_id="O2" value="-30" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma VCAM1 Levels</title>
        <description>Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20mg simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma VCAM1 Levels</title>
          <description>Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44" spread="58"/>
                    <measurement group_id="O2" value="-86" spread="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Plasma TF Levels</title>
        <description>Change in plasma tissue factor (TF) levels after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20mg simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma TF Levels</title>
          <description>Change in plasma tissue factor (TF) levels after treatment with simvastatin</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" spread="32"/>
                    <measurement group_id="O2" value="-36" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Cholesterol Level</title>
        <description>Change in serum total cholesterol level after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20 mg of simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>Subjects received 80 mg daily. Data collected for only 2 participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage&quot;</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol Level</title>
          <description>Change in serum total cholesterol level after treatment with simvastatin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" spread="2"/>
                    <measurement group_id="O2" value="-18" spread="10"/>
                    <measurement group_id="O3" value="-18" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin Level</title>
        <description>Change in plasma hemoglobin (Hb) level after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20 mg of simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Level</title>
          <description>Change in plasma hemoglobin (Hb) level after treatment with simvastatin</description>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="-0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Creatine Kinase Levels</title>
        <description>Change in serum creatine kinase (CK) levels after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20 mg of simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatine Kinase Levels</title>
          <description>Change in serum creatine kinase (CK) levels after treatment with simvastatin</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="88"/>
                    <measurement group_id="O2" value="20" spread="34"/>
                    <measurement group_id="O3" value="62" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Alanine Transaminase (ALT) Levels</title>
        <description>Change in serum alanine transaminase (ALT) after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20 mg of simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Alanine Transaminase (ALT) Levels</title>
          <description>Change in serum alanine transaminase (ALT) after treatment with simvastatin</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="3"/>
                    <measurement group_id="O2" value="3" spread="4"/>
                    <measurement group_id="O3" value="-3" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Creatinine Levels</title>
        <description>Change in serum creatinine (Cr) levels after treatment with simvastatin</description>
        <time_frame>Baseline, 21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin, Dose Level 1</title>
            <description>All participants received 20 mg of simvastatin once daily</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin, Dose Level 2</title>
            <description>All participants received 40 mg of simvastatin once daily</description>
          </group>
          <group group_id="O3">
            <title>Simvastatin, Dose Level 3</title>
            <description>subject received 80 mg daily; only descriptive clinical data collected for participants enrolled in Dose Level 3 (80mg/day) due to discontinuation for recent FDA restriction on daily dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine Levels</title>
          <description>Change in serum creatinine (Cr) levels after treatment with simvastatin</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.03"/>
                    <measurement group_id="O2" value="0.04" spread="0.06"/>
                    <measurement group_id="O3" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>39 days</time_frame>
      <desc>Participants were assessed at day 0 (baseline), day 7, 14, 21 (treatment), day 25 (after taper)and day 39 (follow-up after discontinuation of treatment).</desc>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin, Dose 1</title>
          <description>Simvastatin given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
Dose 1 = 20mg/day for 21 days, followed by 4-day drug taper.</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin, Dose 2</title>
          <description>Simvastatin given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
Dose 2 = 40mg/day for 21 days, followed by a 4-day taper.</description>
        </group>
        <group group_id="E3">
          <title>Simvastatin, Dose 3</title>
          <description>Simvastatin given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
Dose 3 = 80mg/day for 21 days, followed by 4-day drug taper. Enrollment in this group discontinued early due to FDA warning re. high dose simvastatin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>sickle cell acute chest syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>sickle cell vaso-occlusive pain episode</sub_title>
                <description>vaso-occlusive pain event requiring hospitalization, parenteral opioid treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>sickle cell vaso-occlusive pain event</sub_title>
                <description>vaso-occlusive pain event, requiring oral opioids, not hospitalized</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>elevated serum creatine kinase level</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Increase in serum creatine kinase (CK) levels:
4 subjects: asymptomatic (AE, grade 1) 2 subjects: with myalgias (AE, grade 2)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <description>muscle pain associated with increase in serum creatine kinase level. occurred in 2 subjects:
simvastatin, 40mg/day, day 4: creatine kinase &gt;2X UNL with muscle aches
simvastatin, 80mg/day, day 6: creatine kinase &gt;4X UNL with muscle aches</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carolyn Hoppe, Principal Investigator</name_or_title>
      <organization>Children's Hospital &amp; Research Center Oakland</organization>
      <phone>(510)428-3193</phone>
      <email>choppe@mail.cho.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

